Expressiveness of SETAFs and Support-Free ADFs under 3-valued Semantics

Generalizing the attack structure in argumentation frameworks (AFs) has been studied in different ways. Most prominently, the binary attack relation of Dung frameworks has been extended to the notion of collective attacks. The resulting formalism is often termed SETAFs. Another approach is provided via abstract dialectical frameworks (ADFs), where acceptance conditions specify the relation between arguments; restricting these conditions naturally allows for so-called support-free ADFs. The aim of the paper is to shed light on the relation between these two different approaches. To this end, we investigate and compare the expressiveness of SETAFs and support-free ADFs under the lens of 3-valued semantics. Our results show that it is only the presence of unsatisfiable acceptance conditions in support-free ADFs that discriminate the two approaches

Computational Complexity of Strong Admissibility for Abstract Dialectical Frameworks

Abstract dialectical frameworks (ADFs) have been introduced as a formalism for modeling and evaluating argumentation allowing general logical satisfaction conditions. Different criteria used to settle the acceptance of arguments arecalled semantics. Semantics of ADFs have so far mainly been defined based on the concept of admissibility. Recently, the notion of strong admissibility has been introduced for ADFs. In the current work we study the computational complexityof the following reasoning tasks under strong admissibility semantics. We address 1. the credulous/skeptical decision problem; 2. the verification problem; 3. the strong justification problem; and 4. the problem of finding a smallest witness of strong justification of a queried argument

Spectroscopy of 3, 4, 9, 10-perylenetetracarboxylic dianhydride (PTCDA) attached to rare gas samples: Clusters vs. bulk matrices. II. Fluorescence emission spectroscopy

The interaction between 3, 4, 9, 10-perylenetetracarboxylic dianhydride (PTCDA) molecules and solid rare gas samples is studied by means of fluorescence emission spectroscopy. Laser-excited PTCDA-doped large argon, neon, and para-hydrogen clusters along with PTCDA embedded in helium nanodroplets are spectroscopically characterized with respect to line broadening and shifting. A fast non-radiative relaxation is observed before a radiative decay in the electronic ground state takes place. In comparison, fluorescence emission studies of PTCDA embedded in bulk neon and argon matrices result in much more complex spectral signatures characterized by a splitting of the different emission lines. These can be assigned to the appearance of site isomers of the surrounding matrix lattice structure. (C) 2012 American Institute of Physics. [http://dx.doi.org/10.1063/1.4759445

Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study.

ObjectiveTo assess the efficacy and safety of enzyme replacement therapy (ERT) with BMN 110 (elosulfase alfa) in patients with Morquio A syndrome (mucopolysaccharidosis IVA).MethodsPatients with Morquio A aged ≥5 years (N = 176) were randomised (1:1:1) to receive elosulfase alfa 2.0 mg/kg/every other week (qow), elosulfase alfa 2.0 mg/kg/week (weekly) or placebo for 24 weeks in this phase 3, double-blind, randomised study. The primary efficacy measure was 6-min walk test (6MWT) distance. Secondary efficacy measures were 3-min stair climb test (3MSCT) followed by change in urine keratan sulfate (KS). Various exploratory measures included respiratory function tests. Patient safety was also evaluated.ResultsAt week 24, the estimated mean effect on the 6MWT versus placebo was 22.5 m (95 % CI 4.0, 40.9; P = 0.017) for weekly and 0.5 m (95 % CI -17.8, 18.9; P = 0.954) for qow. The estimated mean effect on 3MSCT was 1.1 stairs/min (95 % CI -2.1, 4.4; P = 0.494) for weekly and -0.5 stairs/min (95 % CI -3.7, 2.8; P = 0.778) for qow. Normalised urine KS was reduced at 24 weeks in both regimens. In the weekly dose group, 22.4 % of patients had adverse events leading to an infusion interruption/discontinuation requiring medical intervention (only 1.3 % of all infusions in this group) over 6 months. No adverse events led to permanent treatment discontinuation.ConclusionsElosulfase alfa improved endurance as measured by the 6MWT in the weekly but not qow dose group, did not improve endurance on the 3MSCT, reduced urine KS, and had an acceptable safety profile